Thrombotic Thrombocytopenic Purpura (TTP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Thrombotic thrombocytopenic purpura (TTP) is a form of microangiopathic hemolytic anemia characterized by the classic pentad of symptoms: fever, thrombocytopenia, hemolytic anemia, renal dysfunction, and neurologic dysfunction. TTP arises from a deficiency or absence of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13), either congenital or acquired. Reduced levels of ADAMTS13 lead to the formation of microthrombi, resulting in ischemic damage to various organs. ADAMTS13 cannot effectively inhibit the large multimer von Willebrand factor (VWF), crucial for preventing spontaneous coagulation. Differential diagnoses encompass other thrombotic microangiopathies (TMAs), such as hemolytic uremic syndrome and TMA, secondary to factors like transplantation, chemotherapy, drugs, HIV/AIDS, and HELLP syndrome. Other conditions include catastrophic antiphospholipid syndrome, severe sepsis, vitamin B12 deficiency, malignant hypertension, and disseminated intravascular coagulopathy. Due to the severity of TTP and the risk of sudden organ failure, it is advisable to manage patients in intensive care units until their platelet count returns to normal. The current standard treatment regimen involves plasma exchange to replenish active ADAMTS13 from donor plasma (and, to a lesser extent, remove anti-ADAMTS13 antibodies and pro-aggregate substances). Immunosuppressive therapies like glucocorticoids and rituximab are administered to prevent the production of ADAMTS13 antibodies, and caplacizumab, a nanobody targeting von Willebrand factor (VWF), is employed to expedite platelet count recovery and prevent adverse outcomes. Without intervention, the mortality rate for thrombotic thrombocytopenic purpura is 90%. However, early treatment involving plasma exchange and corticosteroids reduces mortality by 15%. The longer a patient delays seeking treatment, the greater the likelihood of experiencing unfavorable outcomes.
• In the United States, the annual incidence of TTP ranges from 3 to 11 cases per million people.

Thelansis’s “Thrombotic Thrombocytopenic Purpura (TTP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thrombotic Thrombocytopenic Purpura (TTP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Thrombotic Thrombocytopenic Purpura (TTP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Thrombotic Thrombocytopenic Purpura (TTP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Thrombotic Thrombocytopenic Purpura (TTP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033